Adaptive Designs in Clinical Drug Development—An Executive Summary of the PhRMA Working Group-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Adaptive Designs in Clinical Drug Development—An Executive Summary of the PhRMA Working Group

Published:2006-07-01 Issue:3 Volume:16 Page:275-283
ISSN:1054-3406
Container-title:Journal of Biopharmaceutical Statistics
language:en
Short-container-title:Journal of Biopharmaceutical Statistics

Author:

Gallo Paul¹,Chuang-Stein Christy²,Dragalin Vladimir³,Gaydos Brenda⁴,Krams Michael⁵,Pinheiro José¹

Affiliation:

1. a Novartis Pharmaceuticals , East Hanover, New Jersey, USA

2. b Pfizer Inc. , Ann Arbor, Michigan, USA

3. c GlaxoSmithKline Pharmaceuticals , Collegeville, Pennsylvania, USA

4. d Eli Lilly and Company , Indianapolis, Indiana, USA

5. e Pfizer Inc. , Groton, Connecticut, USA

Publisher

Informa UK Limited

Subject

Pharmacology (medical),Pharmacology,Statistics and Probability

Link

https://www.tandfonline.com/doi/pdf/10.1080/10543400600614742

Reference20 articles.

1. Evaluation of Experiments with Adaptive Interim Analyses

2. The advantages and disadvantages of adaptive designs for clinical trials

3. Bayesian Statistics and the Efficiency and Ethics of Clinical Trials

4. Recursive Combination Tests

Cited by 244 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Sample Size Reestimation in Stochastic Curtailment Tests With Time‐to‐Events Outcome in the Case of Nonproportional Hazards Utilizing Two Weibull Distributions With Unknown Shape Parameters;Pharmaceutical Statistics;2024-08-18

2. A landscape of methodology and implementation of adaptive designs in cancer clinical trials;Critical Reviews in Oncology/Hematology;2024-08

3. Seamless phase 2/3 design for trials with multiple co-primary endpoints using Bayesian predictive power;BMC Medical Research Methodology;2024-01-17

4. Adapting dose–response methodology to improve clinical trial design for psychotherapies;International Journal of Eating Disorders;2023-12-22

5. Application of sample size re-estimation in clinical trials: A systematic review;Contemporary Clinical Trials Communications;2023-12

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3